Logic | $4,300,000 | (Oct 21, 2025)
Faeth Therapeutics | $25,000,000 | (Oct 21, 2025)
Avid | $6,500,000 | (Oct 21, 2025)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Adaptyx Biosciences | $14,000,000 | (Oct 21, 2025)
Andel | $4,500,000 | (Oct 21, 2025)
Triplemoon | $3,500,000 | (Oct 21, 2025)
Magic(US) | $10,000,000 | (Oct 21, 2025)
CoMind | $60,000,000 | (Oct 21, 2025)
Armstrong Robotics | $12,000,000 | (Oct 21, 2025)
AdsGency AI | $12,000,000 | (Oct 21, 2025)
Chatfuel | $1,500,000 | (Oct 21, 2025)
Fourier Health | $8,400,000 | (Oct 21, 2025)